Should You Stock Up on Compounded GLP-1? Shelf Life, Storage & What the FDA’s 503B Proposal Means for Your Supply

On April 30, 2026, the FDA proposed removing semaglutide, tirzepatide, and liraglutide from the 503B bulks list—the regulatory pathway that allows outsourcing facilities to compound these medications at scale. Public comments are open until June 29, 2026, and a final decision could come shortly after.

If you’re currently using compounded GLP-1 medication, a rational question follows: should you stock up?

The answer isn’t a simple yes or no. It depends on the format of your medication, how you store it, and how realistic it is to maintain potency over time. This guide breaks down the actual shelf life of every compounded GLP-1 format, proper storage protocols, and what steps make practical sense right now.

The Regulatory Situation: What’s Actually Happening

Let’s separate signal from noise. Here is the current timeline as of May 2026:

• February 2025: FDA resolved the semaglutide injection shortage and removed it from the shortage list.
• Late 2024: Tirzepatide injection shortage was resolved.
• May 2025: Grace periods for compounding “essentially a copy” of FDA-approved products ended for both 503A and 503B facilities.
• 2025: The FDA issued 50+ warning letters to compounders and telehealth companies.
• April 30, 2026: FDA proposed removing semaglutide, tirzepatide, and liraglutide from the 503B bulks list entirely, citing no current clinical need for bulk compounding.
• June 29, 2026: Comment period closes. A final rule could follow within months.

Multiple court challenges are still working through the system, including cases in the 5th Circuit challenging FDA’s shortage authority. The legal landscape is unresolved. But the direction of regulatory travel is clear: compounded GLP-1 access is narrowing.

How Long Does Compounded GLP-1 Actually Last? Shelf Life by Format

Before deciding whether stocking up makes sense, you need to understand how long each format remains viable. The term to know here is beyond-use date (BUD)—the date after which a compounded preparation should not be used. Unlike FDA-approved products with manufacturer expiration dates based on extensive stability testing, BUDs for compounded medications are set by the compounding pharmacy based on USP (United States Pharmacopeia) standards and any stability data they’ve generated.

Injectable Vials: The 30–90 Day Window

Most people on compounded semaglutide or tirzepatide receive pre-mixed injectable vials. These are sterile preparations governed by USP <797>, and their BUD is determined by the compounding environment:

• Category 1 CSPs (prepared in a segregated compounding area): Maximum BUD of 24 hours refrigerated.
• Category 2 CSPs (prepared in a cleanroom suite): BUD up to 60 days refrigerated, or 90 days frozen with sterility testing.
• Category 3 CSPs (highest-level facility controls with full stability and sterility testing): BUD up to 180 days.

In practice, most 503B outsourcing facilities assign BUDs of 60–90 days for refrigerated injectable semaglutide. Some 503A pharmacies assign shorter BUDs of 28–30 days due to less rigorous facility requirements.

Lyophilized Powder: The Longest Shelf Life Option

Lyophilized (freeze-dried) semaglutide and tirzepatide powder represents the most shelf-stable format. Before reconstitution, the powder can maintain potency for months to potentially years when stored properly at refrigerator temperature. Some third-party testing suggests lyophilized peptides stored in a freezer show minimal degradation over extended periods.

The critical limitation: once you add bacteriostatic water to reconstitute the powder into injectable solution, the clock starts ticking. You then have approximately 28–30 days of refrigerated stability.

If your provider offers lyophilized powder, this is theoretically the format most amenable to building a small reserve. However, reconstitution requires proper technique, bacteriostatic water, and sterile supplies. Not all patients are comfortable with this process, and dosing errors from self-reconstitution have been flagged by the FDA—the agency has received over 455 adverse event reports linked to compounded semaglutide, many involving dosing mistakes from multi-dose vials.

Sublingual and Oral Formats

Sublingual drops and troches are compounded as non-sterile preparations under USP <795>. Their BUD depends on the specific formulation, water activity, and preservatives used. Non-aqueous dosage forms (like tablets and certain troches) with low water activity can receive BUDs up to 180 days under the revised USP <795> standards—making them potentially more stockpile-friendly than liquid injectables.

That said, sublingual and oral semaglutide have lower bioavailability compared to injectables, meaning higher doses are typically required to achieve equivalent therapeutic effect. Discuss this trade-off with your provider.

Storage Essentials: The Non-Negotiable Rules

Regardless of format, improper storage will destroy your medication long before the BUD arrives.

Refrigeration Requirements

• Temperature: 36–46°F (2–8°C). Use a thermometer in your refrigerator to verify. The door shelf is the worst spot due to temperature fluctuations—store vials on a middle shelf toward the back.
• Light protection: Keep medication in original packaging or an opaque container. Peptide bonds degrade under UV and fluorescent light exposure.
• Never freeze liquid formulations: Freezing can damage the molecular structure of reconstituted peptides. Lyophilized powder may tolerate freezer storage pre-reconstitution, but confirm with your pharmacy.
• Avoid temperature cycling: Repeatedly taking a vial out for injection and leaving it on the counter will accelerate degradation. Remove, draw your dose, and return to the fridge promptly.

Signs of Degraded Medication

Do not use compounded semaglutide or tirzepatide if you observe any of the following:

• Cloudiness, discoloration, or visible particles in a solution that was previously clear
• Color change outside the expected range (compounded tirzepatide with B12 typically ranges from light yellow to light pink)
• Unusual odor
• Vial seal appears compromised or the rubber stopper is discolored

So Should You Actually Stock Up? A Practical Framework

Here’s a decision framework based on your situation:

Scenario 1: You’re on Injectable Liquid Vials

Stocking up is limited. You can reasonably hold 1–2 extra months of supply (within BUD), but you cannot build a long-term reserve. The medication will expire. Focus instead on ensuring your provider has a continuity plan—ask them directly what happens to your prescription if 503B compounding is restricted.

Scenario 2: You Can Get Lyophilized Powder

This is your best option for a modest reserve. Unreconstituted lyophilized powder has the longest shelf life. If your provider offers this format, ordering 3–6 months of powder ahead of a potential supply disruption is reasonable—provided you’re comfortable with reconstitution and have proper supplies. Store the powder refrigerated or frozen per pharmacy instructions.

Scenario 3: You Use Sublingual or Oral Formats

Check BUD carefully. Non-aqueous oral formulations may have BUDs up to 180 days, giving you a meaningful stockpile window. Ask your pharmacy what the assigned BUD is for your specific formulation before ordering extra.

Scenario 4: You Haven’t Started Yet

Start now if you qualify and want compounded access. Waiting increases the risk of supply disruption. Many reputable providers still operate legally under 503A and existing 503B pathways. The regulatory changes are not retroactive to existing patients with active prescriptions, but new access could become harder.

What “Stocking Up” Does NOT Mean

To be clear: we are not suggesting hoarding, purchasing from unverified sources, or doing anything outside your provider’s guidance. Specifically:

• Do not buy from “research peptide” suppliers. These are unregulated, not intended for human use, and may contain incorrect doses or contaminants. The FDA has specifically warned about this.
• Do not stockpile beyond what you can reasonably use within BUD. Expired compounded medication is not worth the risk.
• Do not adjust your dosing schedule to “stretch” supply. Inconsistent dosing undermines the therapeutic benefit and can cause rebound appetite effects.
• Do not freeze reconstituted liquid medication unless your pharmacy explicitly confirms their specific formulation tolerates freezing.

The Bigger Picture: What Are Your Options if Compounded Supply Shrinks?

If the FDA finalizes the 503B bulks list removal, compounded GLP-1s won’t vanish overnight—but availability will contract significantly. Here are the realistic alternatives:

• 503A patient-specific compounding: Still legal. Your doctor can write a prescription for a specific patient that a 503A pharmacy fills individually. Volume will be lower and potentially more expensive.
• Brand-name medications: Wegovy (semaglutide) lists at roughly $1,349/month; Zepbound (tirzepatide) at around $1,086/month for lower doses via Eli Lilly’s direct-to-consumer program. Some manufacturer savings programs and copay cards exist for insured patients.
• Insurance coverage: More insurers are covering GLP-1s for weight management than in 2024, though prior authorization remains common. Check your plan.
• Oral semaglutide (Rybelsus): FDA-approved for type 2 diabetes; oral Wegovy was FDA-approved in late 2025. Brand-name, not compounded, but eliminates the injection barrier.

Bottom Line

The practical answer to “should I stock up?” depends on format:

• Liquid injectables: Limited window. Keep 1–2 months ahead; focus on provider continuity planning.
• Lyophilized powder: Best option for a modest reserve (3–6 months pre-reconstitution).
• Oral/sublingual: Check your BUD; non-aqueous formats may offer up to 6 months of shelf life.

The FDA’s proposed 503B bulks list removal is not yet finalized. The June 29, 2026 comment deadline is the next key date. In the meantime, the smartest move is to have an honest conversation with your provider about their compounding source, your medication’s actual shelf life, and a backup plan if access narrows.

This article will be updated as the regulatory situation develops.